theranostics
Norroy Starts Phase III Trial for Prostate Cancer Therapy
Norroy Bioscience Co., Ltd., a private clinical-stage radiopharmaceutical company based in Wuxi, China, announced on September 2 that China’s National Medical Products Administration (NMPA) has cleared it to begin a pivotal Phase III trial of 177Lu-NYM032, an investigational PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). Norroy is privately held and does not trade…
